Routine painless gastroscopy
Conditions
Interventions
Group R1:0.1mg/kg remimazzolam tosylate+propofol 0.5mg/kg, and propofol 0.5mg/kg/ time as needed.
Group R2:0.15mg/kg rimazolam tosylate+propofol 0.5mg/kg, and propofol 0.5mg/kg/ time as needed.
Group P:Propofol 1.5mg/kg, IV 1min, and propofol 0.5mg/kg/ time as needed.
Sponsors
The Third Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
65 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1)65=age=75 years old, gender is not limited; 2)Patients receiving routine gastroscopy treatment; 3)ASA scores I to III; 4)18 kg/m2<BMI<30kg/m2; 5)The gastroscope operation time is expected to be less than 30min; 6)Understand and voluntarily participate in the research, and sign the informed consent form by himself.
Exclusion criteria
Exclusion criteria: 1)Patients with mental and psychological diseases and nervous system diseases; 2)Patients who take antipsychotic drugs such as diazepam and anti-anxiety, and who drink or abuse drugs; 3)Patients with language communication, vision or hearing impairment; 4)Complex endoscopic diagnosis and treatment techniques are required (such as cholangiopancreatography, endoscopic ultrasonography, endoscopic mucosal resection, endoscopic submucosal dissection, peroral endoscopic myotomy, etc.); 5)Patients to be intubated; It is judged as a patient with respiratory tract management difficulty (modified Mallampati score is grade IV); 6)Hypertensive patients whose blood pressure is not satisfactorily controlled by antihypertensive drugs (sitting systolic pressure ?160mmHg in screening period and/or diastolic pressure ?100mmHg in screening period); 7)SBP Grade 2, basic SpO2<92%); 10)Severe liver damage; 11) Severe renal impairment; 12)Allergic or contraindicated to benzodiazepines, propofol and their pharmaceutical components; 13)In the past 3 months, as a subject, he has participated in clinical trials of ramizolam or other drugs; 14)The researcher thinks that it is inappropriate to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiopulmonary adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of perioperative cognitive function; | — |
Countries
China
Contacts
Public ContactWen Ouyang
Outcome results
None listed